期刊
TRANSLATIONAL ANDROLOGY AND UROLOGY
卷 7, 期 3, 页码 459-471出版社
AME PUBL CO
DOI: 10.21037/tau.2018.06.02
关键词
Prostate; prostate cancer; biomarker; prostate-specific antigen (PSA); exosome; 4kscore; decipher; Genomic Prostate Score; Prolaris; Michigan Prostate Score; prostate cancer antigen 3 (PCA3); Prostate Health Index
Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer. The evidence base for these assays is rapidly evolving. With several commercial assays available at each stage of the disease, deciding which genomic assays are appropriate for which patients can be nuanced for physicians. In an effort to help guide these decisions in clinical practice, we aim to give an update on the current status of the biomarker field of prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据